Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 10/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | XBP1 | P17861 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30043922 | 1.00 | RAD51 (0.81) | RAD51ALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL25023426 | 0.94 | RAD51 (0.78) | RAD51ALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL30175810 | 0.94 | RAD51 (0.78) | RAD51ALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL30043890 | 0.94 | RAD51 (0.79) | RAD51ALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL23511050 | 0.94 | RAD51 (0.79) | RAD51ALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL23510900 | 0.93 | RAD51 (0.75) | RAD51ALDH1A1KDM4EGAA | |
| SCHEMBL30045170 | 0.93 | KDM4E (0.81) | RAD51ALDH1A1KDM4EGAA | |
| SCHEMBL23498104 | 0.93 | KDM4E (0.81) | RAD51ALDH1A1KDM4EGAA | |
| SCHEMBL23510963 | 0.92 | RAD51 (0.76) | RAD51ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL30043863 | 0.92 | RAD51 (0.76) | RAD51ALDH1A1KDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052747-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | TES PHARMA S.R.L. (IT) | 2023-02-16 | — | — | US | disclosed |
| WO-2021116999-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021116999-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230052747-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | RAD51, BRCA1, FANCI | RAD51 1/4885ALDH1A1 2270/4885KDM4E 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.